Stock Price
3.02
Daily Change
0.05 1.68%
Monthly
-3.21%
Yearly
106.85%
Q1 Forecast
2.88

Galectin Therapeutics reported $25.6M in Cash and Equivalent for its fiscal quarter ending in June of 2024.





Cash And Equivalent Change Date
AbbVie USD 5.23B 400M Dec/2025
Bristol-Myers Squibb USD 10.21B 5.52B Dec/2025
Galectin Therapeutics USD 25.6M 2.04M Jun/2024
Gilead Sciences USD 7.33B 2.19B Sep/2025
Immunic USD 35.13M 20.18M Sep/2025
Incyte USD 3.58B 650.78M Dec/2025
Merck USD 18.17B 10.16B Sep/2025